25-05-09	Carmat: Invest Securities raises target price
25-04-11	Carmat: Invest Securities still a buyer, but cuts TP
25-02-04	Carmat: Invest Securities slightly lowers its target
25-01-09	Carmat: Invest Securities upgrades to buy
25-01-09	Carmat: Oddo BHF reduces its price target

More recommendations

News in other languages: CARMAT

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

More news

Managers and Directors: CARMAT

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	2016-08-31
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	2018-12-11
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	2025-03-31

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	2017-01-01
Michael Mack BRD	Director/Board Member	79	2017-04-19

More insiders

Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

153

Sector

Medical Equipment, Supplies & Distribution

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

Market Cap	6.15M 7.11M 5.66M 5.3M 9.94M 676M 10.09M 67.16M 26.07M 329M 26.68M 26.11M 1.14B	P/E Ratio 2023	-3.09x	P/E Ratio 2024	-0.95x
Enterprise Value	59.25M 68.53M 54.6M 51.12M 95.85M 6.52B 97.24M 647M 251M 3.17B 257M 252M 10.98B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
25-10-15	CAC 40 Surges on LVMH Results and Easing US-China Tensions
25-10-15	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
25-10-15	Carmat says liquidation review postponed until Nov 25	RE
25-10-01	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE
25-10-01	Carmat: Judiciary administrator has submitted request to convert receivership into liquidation to court	RE

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
25-10-29	CARMAT : Inside Information / Other news releases	PU
25-10-29	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
25-10-15	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-50.96%	-54.87%	-	-	7.08M
STRYKER CORPORATION	+2.15%	+3.65%	-18.07%	+11.25%	117B
SMITH & NEPHEW PLC	-0.31%	+0.04%	+1.12%	-5.11%	12.86B
GLAUKOS CORPORATION	+2.05%	+4.21%	+27.90%	+88.29%	7.29B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.87%	-3.51%	-46.74%	-69.06%	4.12B
DOUBLE MEDICAL TECHNOLOGY INC.	+2.06%	+5.59%	+11.04%	+33.01%	2.49B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+5.46%	+10.30%	-16.96%	-14.78%	1.7B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.67%	-6.39%	+3.63%	-11.43%	1.63B
L&C BIO CO.,LTD	-8.89%	-8.45%	+165.17%	+112.14%	1.49B
Average	-4.99%	+1.07%	+15.89%	+18.04%	18.59B
Weighted average by Cap.	+1.84%	+1.39%	-12.38%	+12.21%

	2023	2024
Net sales	3.84M 4.44M 3.54M 3.31M 6.21M 422M 6.3M 41.93M 16.28M 205M 16.65M 16.3M 711M	7.34M 8.49M 6.77M 6.34M 11.88M 808M 12.05M 80.26M 31.15M 393M 31.88M 31.2M 1.36B
Net income	-53.87M -62.31M -49.65M -46.48M -87.15M -5.93B -88.42M -589M -229M -2.88B -234M -229M -9.99B	-51.4M -59.45M -47.37M -44.34M -83.15M -5.66B -84.36M -562M -218M -2.75B -223M -218M -9.53B
Net Debt	49.64M 57.41M 45.74M 42.83M 80.3M 5.46B 81.47M 542M 211M 2.66B 215M 211M 9.2B	53.1M 61.42M 48.94M 45.81M 85.91M 5.84B 87.15M 580M 225M 2.84B 230M 226M 9.84B

CARMAT Stock OTC Markets

Stocks

CKMTF

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Latest news : CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile